Is Moderna Stock Too Expensive in 2022?

Is Moderna Stock Too Expensive in 2022?

Moderna (NASDAQ: MRNA) stock has soared for the past two years thanks to its leadership in the coronavirus vaccine market. Then, they doubled down on their positions when Moderna commercialized its product and started to generate billions of dollars in revenue and profit. Considering this point, is Moderna stock too expensive?